Promising new combo tackles AIDS-Linked cancer
NCT ID NCT03220022
First seen Apr 19, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This early-phase trial is testing whether adding the targeted drug ibrutinib to standard chemotherapy can safely treat HIV-positive patients with a type of lymphoma. About 46 participants with stage II-IV diffuse large B-cell lymphoma will receive the combination. The main goals are to find the best dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, 60612, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Memorial Hospital West
Pembroke Pines, Florida, 33028, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Montefiore Medical Center - Moses Campus
The Bronx, New York, 10467, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Pennsylvania Hospital
Philadelphia, Pennsylvania, 19107, United States
-
Siteman Cancer Center at Washington University
St Louis, Missouri, 63110, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UCSF Medical Center-Parnassus
San Francisco, California, 94143, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of Illinois College of Medicine - Chicago
Chicago, Illinois, 60612, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ibrutinib (a targeted cancer drug) combined with chemotherapy drugs (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)
What this could lead to
If successful, this could point toward a more effective first-line treatment for AIDS-related lymphoma, potentially improving outcomes for people living with HIV.
What could go wrong
This is an early phase 1 trial with only 46 participants, focused on safety and dosing. It may not lead to a standard treatment, and side effects from the drug combination could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.